Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Mogamulizumab (KW-0761) in HTLV-1 Associated Myelopathy (HAM)
jRCT2080223553Phase 3Completed
- Sponsor
- Kyowa Kirin
- Start
- Jun 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in HTLV-1-associated myelopathy (HAM) comparing Mogamulizumab with Placebo (2 arms). Started Jun 2017; status: completed.
02
Drugs
mogamulizumab
03
Conditions
HTLV-1-associated myelopathy (HAM)
Beyond the preview
Go deeper on jRCT2080223553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223553.